Join to View Full Profile
7200 Cambridge St.Suite 10CHouston, TX 77030
Phone+1 713-798-6841
Dr. Lerner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicineResidency, Urology, 1986 - 1990
Virginia Mason Franciscan HealthResidency, Surgery, 1984 - 1986- Baylor College of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 1990 - Present
TX State Medical License 1985 - 2028
WA State Medical License 1985 - 1987
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Genetic Susceptibility to Bladder Cancer Start of enrollment: 1998 Feb 10
Publications & Presentations
PubMed
- Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy.Parminder Singh, Seth P Lerner
The New England Journal of Medicine. 2026-02-18 - Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.Ernest Kaufmann, Stefanie Aeppli, Andres Affentranger, Nicolas Arnold, Winfried Arnold
Bladder Cancer. 2026-01-16 - Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.Heather H Cheng, Sam Callis, Evan Y Yu, Scott E Delacroix, Alexandra O Sokolova
European Urology Focus. 2026-01-01
Press Mentions
Periop Enfortumab Vedotin Plus Pembrolizumab Shows Strong Efficacy in Cisplatin-Eligible MIBCMarch 2nd, 2026- In Memoriam: Dr. Donald G. SkinnerAugust 12th, 2025
- Understanding What Makes Some Bladder Cancers Resistant to ChemotherapyAugust 4th, 2025
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
